These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 30013560)

  • 41. Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
    Mørk SK; Kadivar M; Bol KF; Draghi A; Westergaard MCW; Skadborg SK; Overgaard N; Sørensen AB; Rasmussen IS; Andreasen LV; Yde CW; Trolle T; Garde C; Friis-Nielsen J; Nørgaard N; Christensen D; Kringelum JV; Donia M; Hadrup SR; Svane IM
    Oncoimmunology; 2022; 11(1):2023255. PubMed ID: 35036074
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development.
    Liang J; Zhao X
    Cancer Biol Med; 2021 May; 18(2):352-71. PubMed ID: 33979069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoantigens: promising targets for cancer therapy.
    Xie N; Shen G; Gao W; Huang Z; Huang C; Fu L
    Signal Transduct Target Ther; 2023 Jan; 8(1):9. PubMed ID: 36604431
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
    Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
    Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthetic multiepitope neoantigen DNA vaccine for personalized cancer immunotherapy.
    Yang X; Fan J; Wu Y; Ma Z; Huang J; Zhang Y; Zhou Z; Mo F; Liu X; Yuan H; Xu Y; Pan L; Chen S
    Nanomedicine; 2021 Oct; 37():102443. PubMed ID: 34303839
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neoantigens and NK Cells: "Trick or Treat" the Cancers?
    Lv D; Khawar MB; Liang Z; Gao Y; Sun H
    Front Immunol; 2022; 13():931862. PubMed ID: 35874694
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Potent Micron Neoantigen Tumor Vaccine GP-Neoantigen Induces Robust Antitumor Activity in Multiple Tumor Models.
    Jing Z; Wang S; Xu K; Tang Q; Li W; Zheng W; Shi H; Su K; Liu Y; Hong Z
    Adv Sci (Weinh); 2022 Aug; 9(24):e2201496. PubMed ID: 35712770
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
    Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
    J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor neoantigens: from basic research to clinical applications.
    Jiang T; Shi T; Zhang H; Hu J; Song Y; Wei J; Ren S; Zhou C
    J Hematol Oncol; 2019 Sep; 12(1):93. PubMed ID: 31492199
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8
    Park KS; Nam J; Son S; Moon JJ
    Biomaterials; 2021 Jul; 274():120844. PubMed ID: 33962217
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
    Roerden M; Nelde A; Walz JS
    Front Immunol; 2019; 10():3004. PubMed ID: 31921218
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Challenges in developing personalized neoantigen cancer vaccines.
    Katsikis PD; Ishii KJ; Schliehe C
    Nat Rev Immunol; 2024 Mar; 24(3):213-227. PubMed ID: 37783860
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neoantigens in precision cancer immunotherapy: from identification to clinical applications.
    Zhang Q; Jia Q; Zhang J; Zhu B
    Chin Med J (Engl); 2022 Jun; 135(11):1285-1298. PubMed ID: 35838545
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies.
    Li J; Li J; Peng Y; Du Y; Yang Z; Qi X
    J Control Release; 2023 Jan; 353():423-433. PubMed ID: 36470333
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current Trends in Neoantigen-Based Cancer Vaccines.
    Ho SY; Chang CM; Liao HN; Chou WH; Guo CL; Yen Y; Nakamura Y; Chang WC
    Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986491
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neoantigen vaccine: an emerging tumor immunotherapy.
    Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
    Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control.
    Tondini E; Arakelian T; Oosterhuis K; Camps M; van Duikeren S; Han W; Arens R; Zondag G; van Bergen J; Ossendorp F
    Oncoimmunology; 2019; 8(11):1652539. PubMed ID: 31646082
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Proteogenomic Platform for Identification of Tumor Specific Antigens.
    Faktor J; Hernychová L; Vojtěšek B; Hupp T
    Klin Onkol; 2018; 31(Suppl 2):102-107. PubMed ID: 31023032
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines.
    Aguilar-Gurrieri C; Barajas A; Rovirosa C; Ortiz R; Urrea V; de la Iglesia N; Clotet B; Blanco J; Carrillo J
    Cancer Immunol Immunother; 2023 Jul; 72(7):2113-2125. PubMed ID: 36820900
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CD40 and CD80/86 signaling in cDC1s mediate effective neoantigen vaccination and generation of antigen-specific CX3CR1
    Yamauchi T; Hoki T; Oba T; Kajihara R; Attwood K; Cao X; Ito F
    Cancer Immunol Immunother; 2022 Jan; 71(1):137-151. PubMed ID: 34037810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.